Business EPS was EUR 1.59, up 8.3% at CER and up 1.9% reported; Reports Q2 IRFS net sales EUR 9.99B, up 6% reported and up 10.1% at CER. Paul Hudson, CEO, “We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi (SNY) will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis Treatment?
- Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis
- Sanofi’s TZIELD® Study: A Potential Game-Changer for Type 1 Diabetes
- Regeneron and Sanofi’s Real-World Asthma Study: A Potential Game Changer
- Sanofi’s Riliprubart Study: A Potential Game-Changer for CIDP Treatment